Results 111 to 120 of about 17,808,763 (160)
Detection of Cervical Intraepithelial Neoplasia Using Hyperspectral Tissue Signatures. [PDF]
IEEE J Transl Eng Health MedJurjut O, Weiss M, Daniel Y, Matovina S, Neis F, Rall K, Schopp K, Henes M, Linzenbold W, Brucker SY, Andress J. +10 moreeuropepmc +1 more sourceAlpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial. [PDF]
Breast Cancer Res TreatHörner M, Tretschock LM, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, Amann N, Cieslik JP, Dannehl D, Deutsch TM, Dimpfl M, Ehlert M, Eichstädt K, Englisch A, Köpke MB, Krückel A, Link T, Müller A, Reinhardt K, Roth J, Schäffler H, Sych L, Tegeler CM, Wichmann C, Banys-Paluchowski M, Princk H, Rody A, Brucker SY, Ditsch N, Ettl J, Fehm T, Hack CC, Hadji P, Hein A, Janni WW, Kolberg HC, Lüftner D, Lux MP, Müller V, Schneeweiss A, Taran FA, Tesch H, Wallwiener D, Marmé F, Seitz S, Belleville E, Hartkopf A, Michel LL, Wallwiener M, Fasching PA, Tauber N. +51 moreeuropepmc +1 more sourceSecond report of registry of the International Society of Uterus Transplantation (ISUTx): international activities 2000-2024. [PDF]
Hum ReprodBrännström M, Racowsky C, Wiik J, Tullius SG, Deans R, Porrett PM, Andraus W, Koon TH, Carmona F, Akouri R, Scollo P, Solanki S, Vivek P, Smith JR, Puntambekar SP, Kim SE, Özkan Ö, Ayoubi JM, Fronek J, Brucker SY. +19 moreeuropepmc +1 more sourcePARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry. [PDF]
NPJ Breast CancerHörner M, Hartkopf A, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, Amann N, Cieslik JP, Tretschock LM, Dannehl D, Deutsch TM, Dimpfl M, Ehlert M, Eichstädt K, Englisch A, Köpke MB, Krückel A, Link T, Müller A, Reinhardt K, Roth J, Schäffler H, Sych L, Tauber N, Tegeler CM, Wichmann C, Banys-Paluchowski M, Princk H, Rody A, Brucker SY, Ditsch N, Ettl J, Fehm T, Hack CC, Hadji P, Hein A, Janni WW, Kolberg HC, Lüftner D, Lux MP, Müller V, Taran FA, Tesch H, Wallwiener D, Marmé F, Seitz S, Belleville E, Michel LL, Wallwiener M, Fasching PA, Schneeweiss A, Maurer C. +52 moreeuropepmc +1 more sourceIntent to Accept a Valley Fever Vaccine for Humans and Dogs and Factors Influencing Intended Uptake: A Cross-Sectional Survey in Two Endemic Regions. [PDF]
J Fungi (Basel)Hermann JN, Kruger SE, Wodniak N, Holland J, Janosick V, Sanchez A, Zuniga-Moya JC, Brucker D, Torres B, Melo KM, Oliveros E, Kuran R, D'Assumpcao C, Johnson RH, Pelt RSV, Bhattachan A, Wagner AL, Head JR. +17 moreeuropepmc +1 more sourceUsing Model-Based Geostatistics to Refine Population-Based Estimates of Trachoma Prevalence: Update from a Technical Consultation. [PDF]
Am J Trop Med HygHarte A, Sasanami M, Burgert-Brucker CR, Bakhtiari A, Bisanzio D, Jimenez C, Solomon AW, Kabona GE, Masika MP, Ngondi J, Ante-Testard PA, Arnold BF, Baayenda G, Cuenca PR, Diggle PJ, Edirweera D, Emerson PM, Fronterre C, Gass K, Newbury L, Hooper PJ, Kamau E, Kebede F, Kyomuhangi I, Lietman TM, McCracken K, Minnery M, Nash SD, Nicholls T, Olobio N, Palmer SL, Saeedzai SA, Somerville S, Stern C, Stukel D, Szwarcwald CL, Talero SL, Yevstigneyeva V, Kello AB, Harding-Esch E, Giorgi E. +40 moreeuropepmc +1 more sourceInvasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial. [PDF]
Int J CancerBeierlein M, Häberle L, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, Brucker C, Janni W, Dall P, Schneeweiss A, Marme F, Sütterlin MW, Ruebner M, Theuser AK, Hofmann NM, Böhm S, Almstedt K, Kellner S, Gass P, Lück HJ, Hein A, Schmatloch S, Kalder M, Uleer C, Juhasz-Böss I, Hanf V, Jackisch C, Müller V, Rack B, Belleville E, Wallwiener D, Rody A, Rauh C, Bayer CM, Uhrig S, Huebner H, Goossens C, Brucker SY, Hack CC, Fehm TN, Fasching PA. +43 moreeuropepmc +1 more source
